RxDoctor Payments Data

Yanni Chen, DO

Family Medicine · Coldwater, MINPI 1437108701

Payments from drug & device makers

$15,260in general payments, 2019–2025

Across 834 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • Otsuka America Pharmaceutical, Inc.$963
  • Lilly USA, LLC$892
  • plus $8K from 48 others

What the payments were for

  • Travel & lodging$5644%
  • Food & beverage$14,48495%
  • Education$2121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,260 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$95,981
Medicare patients
185
Services billed
1,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$84,784
FarxigaDapagliflozin Propanediol76$75,492
RexultiBrexpiprazole40$75,105
JardianceEmpagliflozin50$73,770
XareltoRivaroxaban82$67,306
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$38,450
MounjaroTirzepatide28$33,726
TrulicityDulaglutide29$33,698
JanuviaSitagliptin Phosphate37$23,558
Repatha SureclickEvolocumab21$19,818
JanumetSitagliptin Phos/Metformin Hcl16$16,257
LamictalLamotrigine12$15,758
EliquisApixaban12$15,296
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$8,397
DapagliflozinDapagliflozin Propanediol11$7,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,120$84,78472 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,018$82,61188 claims
Otsuka America Pharmaceutical, Inc.Rexulti$963$75,10540 claims
Boehringer IngelheimJardiance$1,075$73,77050 claims
Lilly USA, LLCMounjaro, Trulicity$892$67,42457 claims
Johnson & JohnsonXarelto$481$67,30682 claims
GSKTrelegy Ellipta, Lamictal, Anoro Ellipta$201$62,60464 claims
MerckJanuvia, Janumet$55$39,81553 claims
PfizerEliquis$632$15,29612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Coldwater

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →